Figure 1.

β-Catenin inhibition induces lymphocyte infiltration in CT26 tumors. Mice bearing CT26 tumors were treated with iCRT14 or vehicle every other day for 12 d. FACS was performed to analyze tumor-infiltrating immune cells. (a) Percentage of CD45⁺ cells in total live cells. (b) Percentage of CD8⁺ T cells (CD45⁺CD3⁺CD8⁺) in CD45⁺ cells. (c) Percentage of conventional CD4⁺ T cells (CD45⁺CD3⁺CD4⁺Foxp3⁻) in CD45⁺ cells. (d) Percentage of NK cells (CD45⁺NKp46⁺CD3⁻) in CD45⁺ cells and total live cells. (e) Percentage of Treg cells (CD45⁺CD3⁺CD4⁺CD25⁺Foxp3⁺) in CD45⁺ cells. (f) Ratios of CD8⁺ T to Treg cells, and conventional CD4⁺ T to Treg cells. (g) Percentages of macrophages (MΦ) (M1: CD45⁺CD11b⁺F4/80⁺ CD206^lowMHC-II^high; M2: CD45⁺CD11b⁺F4/80⁺CD206^highMHC-II^low) and MDSCs (CD45⁺CD11b⁺Gr-1⁺CD11c⁻MHC-II^−/low) in total live cells. (h) Percentages of Ki67⁺ cells in CD8⁺ T, conventional CD4⁺ T, NK and Treg cells. (i) Percentages of Granzyme B⁺ (Gzmb⁺) and IFN-γ⁺ cells in CD8⁺ T and NK cells. * P < .05, n.s. = not significant